Therapeutic interventions to disrupt the protein synthetic machinery in melanoma

The role of IRES trans-acting factors in carcinogenesis

(2015) Mame Daro Faye et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Roles of the translation initiation factor eIF2α serine 51 phosphorylation in cancer formation and treatment

(2015) Antonis E. Koromilas   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Disruption of Proline Synthesis in Melanoma Inhibits Protein Production Mediated by the GCN2 Pathway

(2015) G. R. Kardos et al.   MOLECULAR CANCER RESEARCH

Targeting Translation Dependence in Cancer

(2015) Abba Malina et al.   Oncotarget

Targeting Mnks for Cancer Therapy

(2015) Jinqiang Hou et al.   Oncotarget

Tumor suppression by small molecule inhibitors of translation initiation

(2015) Limo Chen et al.   Oncotarget

DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response

(2015) Laureen Colis et al.   Oncotarget

A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity

(2014) Karita Peltonen et al.   CANCER CELL

Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF-MEK-ERK Pathway in Cancer

(2014) G. L. Johnson et al.   CLINICAL CANCER RESEARCH

Targeting glutamine transport to suppress melanoma cell growth

(2014) Qian Wang et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting ER stress–induced autophagy overcomes BRAF inhibitor resistance in melanoma

(2014) Xiao-Hong Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

(2014) Suzanne L. Topalian et al.   JOURNAL OF CLINICAL ONCOLOGY

Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review

(2014) Hidde M. Kroon et al.   JOURNAL OF SURGICAL ONCOLOGY

Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study

(2014) James Larkin et al.   LANCET ONCOLOGY

Eukaryotic Elongation Factor 2 Kinase Activity Is Controlled by Multiple Inputs from Oncogenic Signaling

(2014) X. Wang et al.   MOLECULAR AND CELLULAR BIOLOGY

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

(2014) Lise Boussemart et al.   NATURE

A census of human RNA-binding proteins

(2014) Stefanie Gerstberger et al.   NATURE REVIEWS GENETICS

Growth inhibitory effects of large subunit ribosomal proteins in melanoma

(2014) Gregory R. Kardos et al.   Pigment Cell & Melanoma Research

Silvestrol induces autophagy and cell death in human melanoma cells

(2014) WL Chen et al.   PLANTA MEDICA

Targeting Arginine-Dependent Cancers with Arginine-Degrading Enzymes: Opportunities and Challenges

(2014) Melissa M. Phillips et al.   Cancer Research and Treatment

Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma

(2013) Roxana S. Dronca et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

(2013) David Lebwohl et al.   Annals of the New York Academy of Sciences

A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): A pilot study in a canine model

(2013) Shinya Fukumoto et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Stressing HbF synthesis: role of translation?

(2013) J.-J. Chen et al.   BLOOD

Role of EIF5A2, a downstream target of Akt, in promoting melanoma cell invasion

(2013) S Khosravi et al.   BRITISH JOURNAL OF CANCER

eIF3c: A potential therapeutic target for cancer

(2013) Rafi Emmanuel et al.   CANCER LETTERS

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Trametinib (GSK1120212) in the treatment of melanoma

(2013) April KS Salama et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma

(2013) Andrew Poklepovic et al.   INVESTIGATIONAL NEW DRUGS

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies

(2013) Shaji K. Kumar et al.   INVESTIGATIONAL NEW DRUGS

Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress

(2013) Amanda Croft et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Proteomic Investigation of the Sinulariolide-Treated Melanoma Cells A375: Effects on the Cell Apoptosis through Mitochondrial-Related Pathway and Activation of Caspase Cascade

(2013) Hsing-Hui Li et al.   Marine Drugs

Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma

(2013) Ralph J. Hauke et al.   MELANOMA RESEARCH

eIF5A Promotes Translation of Polyproline Motifs

(2013) Erik Gutierrez et al.   MOLECULAR CELL

Sinulariolide Induced Hepatocellular Carcinoma Apoptosis through Activation of Mitochondrial-Related Apoptotic and PERK/eIF2α/ATF4/CHOP Pathway

(2013) Yi-Jen Chen et al.   MOLECULES

Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma

(2013) C C Jiang et al.   ONCOGENE

Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network

(2013) Lilyn Daftuar et al.   PLoS One

The nucleolus: an emerging target for cancer therapy

(2013) Nadine Hein et al.   TRENDS IN MOLECULAR MEDICINE

MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition

(2013) N. Wagle et al.   Cancer Discovery

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma

(2013) Jessie Villanueva et al.   Cell Reports

Genetics of Ribosomal Proteins: “Curiouser and Curiouser”

(2013) Tamara Terzian et al.   PLoS Genetics

Dysregulation of RNA polymerase I transcription during disease

(2012) K.M. Hannan et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases

(2012) P. Juarez et al.   CANCER RESEARCH

Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438)

(2012) K. A. Margolin et al.   CLINICAL CANCER RESEARCH

Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner

(2012) J. S. Khalili et al.   CLINICAL CANCER RESEARCH

Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models

(2012) P. J. Roberts et al.   CLINICAL CANCER RESEARCH

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

(2012) Patrick A. Ott et al.   INVESTIGATIONAL NEW DRUGS

ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth

(2012) Lori S. Hart et al.   JOURNAL OF CLINICAL INVESTIGATION

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

(2012) Gerald S Falchook et al.   LANCET

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations

(2012) J. G. Greger et al.   MOLECULAR CANCER THERAPEUTICS

Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase

(2012) Tracy L Keller et al.   Nature Chemical Biology

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional Specialization in Proline Biosynthesis of Melanoma

(2012) Jessica De Ingeniis et al.   PLoS One

Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC

(2012) W. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Emerging Therapeutics Targeting mRNA Translation

(2012) A. Malina et al.   Cold Spring Harbor Perspectives in Biology

The Elongation, Termination, and Recycling Phases of Translation in Eukaryotes

(2012) T. E. Dever et al.   Cold Spring Harbor Perspectives in Biology

The Proline Regulatory Axis and Cancer

(2012) James Ming Phang et al.   Frontiers in Oncology

Defective Regulation of Autophagy upon Leucine Deprivation Reveals a Targetable Liability of Human Melanoma Cells In Vitro and In Vivo

(2011) Joon-Ho Sheen et al.   CANCER CELL

Combinatorial Treatments That Overcome PDGFR -Driven Resistance of Melanoma Cells to V600EB-RAF Inhibition

(2011) H. Shi et al.   CANCER RESEARCH

Therapeutic Inhibition of MAP Kinase Interacting Kinase Blocks Eukaryotic Initiation Factor 4E Phosphorylation and Suppresses Outgrowth of Experimental Lung Metastases

(2011) B. W. Konicek et al.   CANCER RESEARCH

Ribosome-Mediated Specificity in Hox mRNA Translation and Vertebrate Tissue Patterning

(2011) Nadya Kondrashov et al.   CELL

A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer

(2011) D. S. Hong et al.   CLINICAL CANCER RESEARCH

The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation

(2011) Ruoning Wang et al.   IMMUNITY

Interplay between Ribosomal Protein S27a and MDM2 Protein in p53 Activation in Response to Ribosomal Stress

(2011) Xiao-Xin Sun et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Blocking eIF4E-eIF4G Interaction as a Strategy To Impair Coronavirus Replication

(2011) R. Cencic et al.   JOURNAL OF VIROLOGY

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

(2011) Richard Possemato et al.   NATURE

Chemical genetics identify eIF2α kinase heme-regulated inhibitor as an anticancer target

(2011) Ting Chen et al.   Nature Chemical Biology

The biological and therapeutic relevance of mRNA translation in cancer

(2011) Sarah P. Blagden et al.   Nature Reviews Clinical Oncology

Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance

(2011) W Li et al.   ONCOGENE

PHGDH amplification and altered glucose metabolism in human melanoma

(2011) Edouard Mullarky et al.   Pigment Cell & Melanoma Research

siRNA Knockdown of Ribosomal Protein Gene RPL19 Abrogates the Aggressive Phenotype of Human Prostate Cancer

(2011) Alix Bee et al.   PLoS One

Downregulation of RPL6 by siRNA Inhibits Proliferation and Cell Cycle Progression of Human Gastric Cancer Cell Lines

(2011) Qiong Wu et al.   PLoS One

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis

(2011) N. Ilic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Structure of the Eukaryotic Ribosome at 3.0 A Resolution

(2011) A. Ben-Shem et al.   SCIENCE

AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer

(2011) J. C. Chan et al.   Science Signaling

ABT-737 synergizes with Bortezomib to kill melanoma cells

(2011) S. N. Reuland et al.   Biology Open

Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth

(2010) Denis Drygin et al.   CANCER RESEARCH

Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma

(2010) S. A. Aziz et al.   CLINICAL CANCER RESEARCH

Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma

(2010) N. Savaraj et al.   CURRENT MOLECULAR MEDICINE

The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation

(2010) Jiangbin Ye et al.   EMBO JOURNAL

Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels

(2010) Kaspar Burger et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Investigation of the eIF2α phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells

(2010) Azmi Yerlikaya et al.   MOLECULAR BIOLOGY

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26

(2010) Y. Zhang et al.   NUCLEIC ACIDS RESEARCH

Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator

(2010) X Xiong et al.   ONCOGENE

Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway

(2010) C Deisenroth et al.   ONCOGENE

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

(2010) V. E. Kwitkowski et al.   ONCOLOGIST

Silencing of Ribosomal Protein S9 Elicits a Multitude of Cellular Responses Inhibiting the Growth of Cancer Cells Subsequent to p53 Activation

(2010) Mikael S. Lindström et al.   PLoS One

Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F

(2010) R. Cencic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anticancer Activity of CX-3543: A Direct Inhibitor of rRNA Biogenesis

(2009) D. Drygin et al.   CANCER RESEARCH

Regulation of Translation Initiation in Eukaryotes: Mechanisms and Biological Targets

(2009) Nahum Sonenberg et al.   CELL

Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain

(2009) Sridevi Yadavilli et al.   DNA REPAIR

What the nucleolus says to a tumour pathologist

(2009) Massimo Derenzini et al.   HISTOPATHOLOGY

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

(2009) Georg Hess et al.   JOURNAL OF CLINICAL ONCOLOGY

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

(2009) Güliz Gürel et al.   JOURNAL OF MOLECULAR BIOLOGY

Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A

(2009) G. Kuznetsov et al.   MOLECULAR CANCER THERAPEUTICS

How Common Are Extraribosomal Functions of Ribosomal Proteins?

(2009) Jonathan R. Warner et al.   MOLECULAR CELL

Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2

(2009) Yan Zhu et al.   MOLECULAR CELL

Molecular mechanisms of mTOR-mediated translational control

(2009) Xiaoju Max Ma et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Genome-Wide Analysis in Vivo of Translation with Nucleotide Resolution Using Ribosome Profiling

(2009) N. T. Ingolia et al.   SCIENCE

Tumor Suppression by PTEN Requires the Activation of the PKR-eIF2  Phosphorylation Pathway

(2009) Z. Mounir et al.   Science Signaling

RNA-binding proteins and post-transcriptional gene regulation

(2008) Tina Glisovic et al.   FEBS LETTERS

The Mnks: MAP kinase-interacting kinases (MAP kinase signal-integrating kinases)

(2008) Maria Buxade   Frontiers in Bioscience-Landmark

Loss of the eukaryotic initiation factor 3f in melanoma

(2008) Adriana Doldan et al.   MOLECULAR CARCINOGENESIS

Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects

(2008) Kelly A McGowan et al.   NATURE GENETICS

The splice variants of UBF differentially regulate RNA polymerase I transcription elongation in response to ERK phosphorylation

(2008) Victor Y. Stefanovsky et al.   NUCLEIC ACIDS RESEARCH

Proline oxidase, a p53-induced gene, targets COX-2/PGE2 signaling to induce apoptosis and inhibit tumor growth in colorectal cancers

(2008) Y Liu et al.   ONCOGENE

PI3K pathway alterations in cancer: variations on a theme

(2008) T L Yuan et al.   ONCOGENE

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA